Is Combined Bulevirtide and Pegylated Interferon Therapy for Chronic Hepatitis D Superior over Bulevirtide Monotherapy?
Bulevirtide is a novel antiviral agent approved for suppression of chronic hepatitis D but requiring further research into optimising the treatment scheme.Aim. Comparative assessment of bulevirtide monotherapy versus combined treatment with bulevirtide and pegylat-ed interferon (PEG-IFN) using publi...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
Gastro LLC
2020-09-01
|
| Series: | Российский журнал гастроэнтерологии, гепатологии, колопроктологии |
| Subjects: | |
| Online Access: | https://www.gastro-j.ru/jour/article/view/489 |
| Summary: | Bulevirtide is a novel antiviral agent approved for suppression of chronic hepatitis D but requiring further research into optimising the treatment scheme.Aim. Comparative assessment of bulevirtide monotherapy versus combined treatment with bulevirtide and pegylat-ed interferon (PEG-IFN) using published trial data.Key points. MYR201 and MYR203 trials expose a higher frequency of HBsAg and HDV RNA extinction, as well as more effective HDV suppression for combined bulevirtide/PEG-IFN therapy compared to bulevirtide monotherapy.Conclusion. Combined bulevirtide/PEG-IFN therapy has particular advantages over bulevirtide monotherapy in patients with chronic hepatitis D. Further research is required to optimise bulevirtide dosage and duration of therapy. |
|---|---|
| ISSN: | 1382-4376 2658-6673 |